Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 23, 2026

Salesforce: Boring on the Surface, Dangerous to Ignore

View original at finance.yahoo.com
Salesforce: Boring on the Surface, Dangerous to Ignore This article first appeared on GuruFocus. Looking at the current state of the tech market, I see a fascinating disconnect between reality and sentiment…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce is successfully selling the AI agents themselves, opposite to fears that AI will replace human workers and shrink revenue

    80% confidence

  • Management noted that for the first time in years, the deal size for new business is growing faster than the deal size for existing business renewals

    80% confidence

  • Management signaled they are going to accelerate share buybacks in the second half of the fiscal year

    80% confidence

  • Rating Salesforce as 'Strong Buy' with expected fair value of roughly $314 per share

    80% confidence

  • If the stock simply re-rated to its average historical P/E multiple of around 22x, the price would jump to over $280

    80% confidence

  • More than half of the new bookings for AI products (Agentforce and Data Cloud) are coming from existing customers

    80% confidence

  • The narrative has been dominated by fears that artificial intelligence will disrupt Salesforce's business model

    80% confidence

  • The market is treating Salesforce like a boring legacy company that has seen its best days

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Salesforce: Boring on the Surface, Dangerous to Ignore — Source | Via News | ViaNews Market